The global syphilis testing market size was estimated at USD 1.57 billion in 2025 and is projected to reach USD 2.32 billion by 2033, growing at a CAGR of 5.23% from 2026 to 2033. Key market drivers for dual HIV/syphilis rapid diagnostics include the rising global burden of congenital syphilis and HIV co-infections, which continue to cause significant adverse pregnancy outcomes. Increasing awareness regarding sexually transmitted infections (STIs), expanding screening programs, and growing emphasis on early disease detection are contributing to market growth. Healthcare organizations and governments worldwide are strengthening efforts to improve access to diagnostic testing services in order to reduce transmission rates and support timely treatment interventions.

Syphilis testing plays a critical role in identifying infections at an early stage, enabling healthcare providers to initiate appropriate treatment and prevent disease progression. The growing prevalence of syphilis infections, combined with increasing public health initiatives focused on maternal and child health, is driving demand for reliable diagnostic solutions. Technological advancements in testing methods and the increasing availability of rapid diagnostic tests are also supporting the expansion of the market across both developed and developing regions.

Download a free sample copy of the Syphilis Testing market report to understand detailed coverage and inclusions in the final report

Key Market Trends & Insights

• North America dominated the global syphilis testing market with the largest revenue share of 36.32% in 2025. The region benefits from advanced healthcare infrastructure, widespread awareness regarding sexually transmitted infections, and established screening programs. Strong government support for disease prevention initiatives and increasing adoption of advanced diagnostic technologies are contributing to market growth. The presence of leading healthcare institutions and diagnostic companies further strengthens the regional market position.
• The syphilis testing industry in the U.S. accounted for the largest market revenue share in North America in 2025. The country continues to witness significant investments in public health programs aimed at improving STI detection and treatment outcomes. Increasing testing rates, growing awareness campaigns, and expanding access to diagnostic services are supporting market growth. Healthcare providers are increasingly emphasizing routine screening among high-risk populations to improve early diagnosis and disease management.
• By technology, the immunoassay segment led the market with the largest revenue share of 71.20% in 2025. Immunoassay-based testing methods are widely used due to their high sensitivity, accuracy, reliability, and ability to process large sample volumes efficiently. These tests play an important role in detecting syphilis infections across various healthcare settings, including hospitals, laboratories, and diagnostic centers. Their effectiveness in supporting accurate diagnosis has contributed significantly to the segment's dominant market position.
• By location of testing, the laboratory testing segment led the market with the largest revenue share of 79.56% in 2025. Laboratory-based testing remains the preferred approach for syphilis diagnosis due to its ability to provide highly accurate and comprehensive results. Clinical laboratories utilize advanced diagnostic equipment and standardized testing procedures to ensure reliable disease detection. The increasing volume of screening programs, confirmatory testing requirements, and diagnostic evaluations continues to support the leadership of the laboratory testing segment within the global market.

Looking for more specific insights? Customize this report to suite your business needs

Key Companies & Market Share Insights

Market leaders are engaged in extensive R&D to develop technologically advanced, cost-efficient testing products. Besides, several organizations are incorporating strategies such as mergers & acquisitions to expand their market presence and are anticipated to create significant growth opportunities over the forecast period. For instance, in May 2023, Charles Thermo Fisher Scientific, Inc. entered into a partnership with Pfizer Inc. to enhance the availability of localized access to next-generation sequencing-based testing for cancer patients in international markets.

Key Syphilis Testing Companies:

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Bio-Rad Laboratories, Inc.
• Siemens Healthineers AG
• Danaher Corporation (Beckman Coulter)
• Thermo Fisher Scientific Inc.
• bioMérieux SA
• OraSure Technologies, Inc.
• Chembio Diagnostics, Inc.
• SD Biosensor, Inc.

Explore Grand View Horizon to see global and regional level statistics related to the Syphilis Testing Market

Grand View Research offers

• Focused market intelligence reports on specific geographies or high-growth segments.
• Extended forecast timelines for long-term planning.
• Competitor Benchmarking and Supply Chain Analysis
• Inclusion of regulatory and policy assessments.
• Inclusion of custom data models, KPIs, or applications unique to your business
• Specific high-impact Data Decks and Tables to support effective decision making
• And much more…

Looking for a report customized to your requirements? Explore our Custom Research Offering